Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Mylan Expands Voluntary Recall of Select Injectable Products

By Drug Discovery Trends Editor | June 10, 2015

Source: ShutterstockThe U.S. branch of Mylan N.V. announced Monday it would expand a voluntary nationwide recall of injectable drugs that are contaminated with foreign particulate matter. 

Several groups of Gemcitabine and one lot of Methotrexate are the drugs being recalled. The first one can treat multiple forms of cancer whereas the second is intended for severe psoriasis and adult rheumatoid arthritis, as well as certain forms of neoplastic disease. 

The company noticed the presence of the contaminant “during testing of retention samples,” according to the release. Both drugs belong to the class of sterile injectables, a type of medication capable of causing severe health problems if administered when infected with an unknown pollutant. A chance of stroke or respiratory failure are some of the adverse events Mylan cites in the memo.

FiercePharmaManufacturing reports Mylan began the initial recall in April of a cancer drug called carboplatin after finding that it contained foreign particulate matter.

Mylan notes so far there have been no reports regarding these serious reactions.


Filed Under: Drug Discovery

 

Related Articles Read More >

Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority
Portrait photo of Pfizer EVP and Medtronic board member Lidia Fonseca
Medtronic appoints Pfizer EVP as independent board director

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50